Preclinical evidence that 5-HT1B receptor agonists show promise as medications for psychostimulant use disorders

Raul Garcia, Austin R. Cotter, Kenneth Leslie, Michael Olive, Janet Neisewander

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-Administration sessions but decrease cocaine intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinencedependent effects on methamphetamine intake. Methods: Male rats were trained to self-Administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-Administration both before and after a 21-day forced abstinence period during which the rats remained in their home cages. Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre-And postabstinence. Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre-And postabstinence, and the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions. Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B receptor agonists may have clinical efficacy for psychostimulant use disorders.

Original languageEnglish (US)
Pages (from-to)644-653
Number of pages10
JournalInternational Journal of Neuropsychopharmacology
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Receptor, Serotonin, 5-HT1B
Serotonin 5-HT1 Receptor Agonists
Methamphetamine
zolmitriptan
Appointments and Schedules
Cocaine
Self Administration
Serotonin 5-HT1 Receptor Antagonists
Reinforcement Schedule
CP 94253

Keywords

  • Addiction
  • CP 94 253
  • Methamphetamine
  • Rodent
  • Zolmitriptan

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Preclinical evidence that 5-HT1B receptor agonists show promise as medications for psychostimulant use disorders. / Garcia, Raul; Cotter, Austin R.; Leslie, Kenneth; Olive, Michael; Neisewander, Janet.

In: International Journal of Neuropsychopharmacology, Vol. 20, No. 8, 01.08.2017, p. 644-653.

Research output: Contribution to journalArticle

@article{e1affd58dbf543e9847bb982c69c7b0b,
title = "Preclinical evidence that 5-HT1B receptor agonists show promise as medications for psychostimulant use disorders",
abstract = "Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-Administration sessions but decrease cocaine intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinencedependent effects on methamphetamine intake. Methods: Male rats were trained to self-Administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-Administration both before and after a 21-day forced abstinence period during which the rats remained in their home cages. Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre-And postabstinence. Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre-And postabstinence, and the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions. Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B receptor agonists may have clinical efficacy for psychostimulant use disorders.",
keywords = "Addiction, CP 94 253, Methamphetamine, Rodent, Zolmitriptan",
author = "Raul Garcia and Cotter, {Austin R.} and Kenneth Leslie and Michael Olive and Janet Neisewander",
year = "2017",
month = "8",
day = "1",
doi = "10.1093/ijnp/pyx025",
language = "English (US)",
volume = "20",
pages = "644--653",
journal = "The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "8",

}

TY - JOUR

T1 - Preclinical evidence that 5-HT1B receptor agonists show promise as medications for psychostimulant use disorders

AU - Garcia, Raul

AU - Cotter, Austin R.

AU - Leslie, Kenneth

AU - Olive, Michael

AU - Neisewander, Janet

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-Administration sessions but decrease cocaine intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinencedependent effects on methamphetamine intake. Methods: Male rats were trained to self-Administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-Administration both before and after a 21-day forced abstinence period during which the rats remained in their home cages. Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre-And postabstinence. Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre-And postabstinence, and the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions. Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B receptor agonists may have clinical efficacy for psychostimulant use disorders.

AB - Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-Administration sessions but decrease cocaine intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinencedependent effects on methamphetamine intake. Methods: Male rats were trained to self-Administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-Administration both before and after a 21-day forced abstinence period during which the rats remained in their home cages. Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre-And postabstinence. Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre-And postabstinence, and the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions. Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B receptor agonists may have clinical efficacy for psychostimulant use disorders.

KW - Addiction

KW - CP 94 253

KW - Methamphetamine

KW - Rodent

KW - Zolmitriptan

UR - http://www.scopus.com/inward/record.url?scp=85032900789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032900789&partnerID=8YFLogxK

U2 - 10.1093/ijnp/pyx025

DO - 10.1093/ijnp/pyx025

M3 - Article

VL - 20

SP - 644

EP - 653

JO - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

JF - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

SN - 1461-1457

IS - 8

ER -